一分钟看懂
这是一项关于尿路上皮癌的II 期研究，登记的药物或干预包括Enfortumab vedotin；Pembrolizumab，当前状态为招募中。登记地点显示中国Miami、Basking Ridge、Middletown、Montvale等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Enfortumab vedotin；Pembrolizumab · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Baptist Alliance MCI · Miami
- Memorial Sloan Kettering Basking Ridge · Basking Ridge
- Memorial Sloan Kettering Monmouth · Middletown
- Memorial Sloan Kettering Bergen · Montvale
- Memorial Sloan Kettering -Nassau · Commack
- Memorial Sloan Kettering Westchester · Harrison
- Memorial Sloan Kettering Cancer Center · New York
- Memorial Sloan Kettering Nassau · Rockville Centre
- Lehigh Valley Health Network (Data Collection Only) · Allentown
- University of Texas Southwestern Medical Center at Dallas · Dallas
公开的入选条件
- * Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of muscle invasive bladder cancer (previously known as transitional cell) carcinoma (i.e., cancer of the bladder, renal p
- * Clinical Stage T2-T4, N1-N3, M0 OR cT1, N2-N3, M0
- * Pathology:
- Representative urothelial carcinoma FFPE tumor specimens (tumor blocks or 20 unstained slides). Patients with \< 20 slides may be enrolled after discussion with the principal investigator.
- Muscle invasive urothelial carcinoma of the bladder histologically confirmed at the enrolling institution from TURBT. (Urothelial carcinoma invading into the prostatic stroma with no histologic muscle invasion is allowed provided the extent of disease is confi
- Evidence of urothelial carcinoma from FNA of lymph node OR lymphadenopathy suspicious for nodal disease on cross-sectional imaging, MRI, or u/s.
- Node positivity for eligibility will be defined as imaging read with suspicious lymph node ≤ 1.0 cm in the short axis, with biopsy, as documented by the radiologist at the treating center. While biopsy to confirm lymph node involvement is preferred, patients w
- * Deemed medically appropriate for radical cystectomy with treatment response achieved, as per MSK or participating site Attending Urologic Oncologist
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05239624；登记信息更新于 2026-09-17。